Certara, Inc.
CERT- Exchange
- Nasdaq
- Industry
- Services-Prepackaged Software
- SEC CIK
- 0001827090
No open-market purchases or sales by Certara, Inc. insiders were filed in the last 90 days; 241 institutions reported holding it in 13F filings for Q2 2026, worth $880.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Certara, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Certara, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Mohammed Faiz | Interim CFO | – | Sep 2, 2026 | 1 |
| Anhalt Rona | Chief Human Resources Officer | 16,789 | Jun 2, 2026 | 3 |
| Corcoran Daniel | SVP and General Counsel | 32,046 | Jun 2, 2026 | 3 |
| Cashman James E III | Director, Other: Chairman | 484,197 | May 15, 2026 | 1 |
| Broshy Eran | Director, Other: Chairman | 50,708 | May 15, 2026 | 1 |
| Walsh Matthew M | Director | 213,316 | May 15, 2026 | 1 |
| Collins Cynthia | Director | 51,846 | May 15, 2026 | 1 |
| Crane Rosemary A | Director | 45,672 | May 15, 2026 | 1 |
| Killefer Nancy | Director | 51,846 | May 15, 2026 | 1 |
| Reynders John V W | Chief Financial Officer | 26,466 | May 15, 2026 | 1 |
| Bedi Arjun | Director | 5,547 | May 15, 2026 | 2 |
| Pedersen Leif E | PRESIDENT, CHIEF COMMERCAL OFF | 110,045 | May 13, 2026 | 2 |
| Gallagher John E | Chief Financial Officer | 95,371 | May 13, 2026 | 2 |
| Aspbury Robert | PRESIDENT, PREDICTIVE TECH | 332,442 | May 13, 2026 | 2 |
| Resnick Jon Matthew | Chief Executive Officer | 35,389 | May 13, 2026 | 1 |
| McKemey Adrian | President, Drug Dev. Solutions | 8,207 | Apr 3, 2026 | 1 |
| Feehery William F | CHIEF EXECUTIVE OFFICER | 2,360,769 | Nov 12, 2025 | 1 |
| Smith Patrick F | PRESIDENT, DRUG DEV SOLUTIONS | 50,091 | Oct 8, 2024 | 0 |
| Traynor Richard M. | SVP AND GENERAL COUNSEL | 173,524 | Apr 3, 2024 | 0 |
| Sherman Nicolette D | CHIEF HUMAN RESOURCES OFFICER | 24,358 | Apr 3, 2024 | 0 |
| Schemick Michael Andrew | CHIEF FINANCIAL OFFICER | 522,895 | Apr 3, 2023 | 0 |
| Virkler Drayton | PRESIDENT, REG & ACCES | 12,415 | Apr 3, 2023 | 0 |
| EQT Avatar Parent L.P. | 10% Owner | 0Indirect | Dec 12, 2022 | 0 |
| EQT Avatar Parent GP LLC | 10% Owner | 0Indirect | Dec 12, 2022 | 0 |
| EQT Fund Management S.a r.l. | 10% Owner | 0Indirect | Dec 12, 2022 | 0 |
| Slaine Mason P | Director | 660,322 | Nov 16, 2022 | 0 |
| McLean Stephen M. | Director | 42,000 | Aug 23, 2022 | 0 |
| Choe Jieun W. | CHIEF STRATEGY & MARKETING | 248,577 | Apr 5, 2022 | 0 |
| Edge Justin | PRES., REGULATORY & ACCESS | 394,764 | Apr 5, 2022 | 0 |
| Rayner Craig R. | PRESIDENT, INTEGRATED DRUG DEV | 316,010 | Sep 7, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 27, 2021 (view filing) | Dec 23 | 4 days | Cashman James E IIIDirector | SSale | −25.1K | $29.20 | −$733.2K | −5.4%438.8K after | |
| Dec 28, 2021 (view filing) | Dec 27 | 1 day | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −3.00K | $29.30 | −$87.9K | −1.3%222.3K after | |
| Jan 4, 2022 (view filing) | Jan 3 | 1 day | Slaine Mason PDirector | SSale | −50.0K | $28.63 | −$1.43M | −3.0%1.64M after | 2 lots |
| Jan 20, 2022 (view filing) | Jan 18 | 2 days | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −5.00K | $27.44 | −$137.2K | −2.2%217.3K after | |
| Jan 21, 2022 (view filing) | Jan 20 | 1 day | Edge JustinPRES., REGULATORY & ACCESS | SSale | −5.00K | $27.50 | −$137.5K | −1.2%397.1K after | |
| Jan 27, 2022 (view filing) | Jan 26 | 1 day | Feehery William FCHIEF EXECUTIVE OFFICER | SSale | −75.0K | $25.37 | −$1.90M | −3.0%2.43M after | 2 lots |
| Jan 27, 2022 (view filing) | Jan 26 | 1 day | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −3.00K | $26.01 | −$78.0K | −1.4%214.3K after | |
| Feb 2, 2022 (view filing) | Feb 1 | 1 day | Slaine Mason PDirector | SSale | −50.0K | $26.61 | −$1.33M | −3.0%1.59M after | 2 lots |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Feehery William FCHIEF EXECUTIVE OFFICER | SSale | −90.0K | $24.32 | −$2.19M | −3.7%2.34M after | 3 lots |
| Feb 22, 2022 (view filing) | Feb 18 | 4 days | Feehery William FCHIEF EXECUTIVE OFFICER | SSale | −75.0K | $23.35 | −$1.75M | −3.2%2.27M after | 2 lots |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | Feehery William FCHIEF EXECUTIVE OFFICER | SSale | −27.5K | $20.29 | −$558.3K | −1.2%2.24M after | |
| Mar 17, 2022 (view filing) | Mar 16 | 1 day | Feehery William FCHIEF EXECUTIVE OFFICER | SSale | −62.5K | $20.17 | −$1.26M | −2.8%2.18M after | |
| Mar 18, 2022 (view filing) | Mar 16-17 | 2 days | Slaine Mason PDirector | SSale | −250.0K | $20.21 | −$5.05M | −15.7%1.34M after | 2 lots |
| Mar 18, 2022 (view filing) | Mar 16 | 2 days | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −3.00K | $20.00 | −$60.0K | −1.4%211.3K after | |
| Apr 5, 2022 (view filing) | Apr 4 | 1 day | Smith Patrick FPRESIDENT, INTEGRATED DRUG DEV | SSale | −3.35K | $22.29 | −$74.7K | −3.3%98.5K after | |
| Jun 1, 2022 (view filing)6:34 PM ET | May 31 | 1 day | EQT Avatar Parent L.P. and 2 others10% Owner | SSale | −1.50M | $19.00 | −$28.5M | −4.0%36.0M after | |
| Jun 3, 2022 (view filing) | Jun 2 | 1 day | Slaine Mason PDirector | SSale | −250.0K | $19.56 | −$4.89M | −18.6%1.09M after | 3 lots |
| Jun 9, 2022 (view filing) | Jun 8 | 1 day | Smith Patrick FPRESIDENT, INTEGRATED DRUG DEV | SSale | −10.0K | $19.16 | −$191.6K | −10.2%88.5K after | |
| Aug 17, 2022 (view filing) | Aug 16 | 1 day | Slaine Mason PDirector | SSale | −182.5K | $17.38 | −$3.17M | −16.7%910.3K after | |
| Aug 17, 2022 (view filing)5:01 PM ET | Aug 16 | 1 day | EQT Avatar Parent L.P. and 2 others10% Owner | SSale | −6.00M | $17.38 | −$104.4M | −16.7%30.0M after | |
| Aug 18, 2022 (view filing) | Aug 16 | 2 days | Smith Patrick FPRESIDENT, INTEGRATED DRUG DEV | SSale | −10.0K | $17.71 | −$177.1K | −11.3%78.5K after | |
| Aug 18, 2022 (view filing) | Aug 17 | 1 day | Schemick Michael AndrewCHIEF FINANCIAL OFFICER | PPurchase | +25.0K | $16.64 | +$416.0K | +5.1%517.9K after | |
| Aug 23, 2022 (view filing) | Aug 19 | 4 days | McLean Stephen M.Director | PPurchase | +20.0K | $16.32 | +$326.4K | +90.9%42.0K after | |
| Nov 14, 2022 (view filing) | Nov 9 | 5 days | Smith Patrick FPRESIDENT, INTEGRATED DRUG DEV | SSale | −2.39K | $13.48 | −$32.2K | −3.1%74.9K after | |
| Nov 15, 2022 (view filing) | Nov 14 | 1 day | Walsh Matthew MDirector | SSale | −12.1K | $14.74 | −$177.7K | −6.7%167.9K after | |
| Nov 16, 2022 (view filing) | Nov 14-15 | 2 days | Slaine Mason PDirector | SSale | −250.0K | $15.56 | −$3.89M | −27.5%660.3K after | 2 lots |
| Nov 23, 2022 (view filing) | Nov 22 | 1 day | Pedersen Leif EPRESIDENT, SOFTWARE | SSale | −51.2K | $15.55 | −$796.5K | −22.6%175.5K after | |
| Dec 12, 2022 (view filing)4:16 PM ET | Dec 8 | 4 days | EQT Avatar Parent L.P. and 2 others10% Owner | SSale | −30.0M | $15.00 | −$449.3M | −100.0%0 after | |
| Feb 3, 2023 (view filing) | Feb 2 | 1 day | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −15.0K | $20.00 | −$300.0K | −7.2%194.6K after | |
| Mar 7, 2023 (view filing) | Mar 6 | 1 day | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −10.0K | $21.45 | −$214.5K | −5.1%184.6K after | |
| Apr 17, 2023 (view filing) | Apr 14 | 3 days | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −5.00K | $23.66 | −$118.3K | −2.7%182.4K after | 10b5-1 |
| May 15, 2023 (view filing) | May 11 | 4 days | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −5.00K | $20.82 | −$104.1K | −2.7%177.4K after | 10b5-1 |
| Jun 6, 2023 (view filing) | Jun 5 | 1 day | Smith Patrick FPRESIDENT, INTEGRATED DRUG DEV | SSale | −19.1K | $21.55 | −$411.7K | −24.2%60.0K after | 10b5-1 |
| Aug 23, 2023 (view filing) | Aug 21-22 | 2 days | Broshy EranDirector | PPurchase | +5.00K | $15.81 | +$79.1K | +53.4%14.4K after | 2 lots |
| Sep 12, 2023 (view filing) | Sep 11 | 1 day | Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF | SSale | −51.2K | $14.60 | −$747.9K | −28.4%128.9K after | 10b5-1 |
| Dec 27, 2023 (view filing) | Dec 26 | 1 day | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −6.00K | $18.00 | −$108.0K | −3.4%171.4K after | 10b5-1 |
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −6.00K | $18.00 | −$108.0K | −3.5%165.4K after | 10b5-1 |
| Feb 21, 2024 (view filing) | Feb 20 | 1 day | Smith Patrick FPRESIDENT, DRUG DEV SOLUTIONS | SSale | −5.00K | $18.00 | −$90.0K | −8.3%55.0K after | 10b5-1 |
| Mar 5, 2024 (view filing) | Mar 4 | 1 day | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −3.00K | $18.28 | −$54.8K | −1.8%162.4K after | 10b5-1 |
| Apr 3, 2024 (view filing) | Apr 1 | 2 days | Traynor Richard M.SVP AND GENERAL COUNSEL | SSale | −3.00K | $18.00 | −$54.0K | −1.7%173.5K after | 10b5-1 |
| Apr 4, 2024 (view filing) | Apr 2 | 2 days | Smith Patrick FPRESIDENT, DRUG DEV SOLUTIONS | SSale | −14.4K | $16.85 | −$243.2K | −22.4%50.1K after | 6 lots10b5-1 |
| Sep 10, 2024 (view filing) | Sep 9 | 1 day | Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF | SSale | −51.2K | $11.29 | −$578.3K | −33.9%99.7K after | 10b5-1 |
| Oct 8, 2024 (view filing) | Oct 7 | 1 day | Smith Patrick FPRESIDENT, DRUG DEV SOLUTIONS | SSale | −5.41K | $11.03 | −$59.7K | −9.7%50.1K after | 10b5-1 |
| Sep 11, 2025 (view filing) | Sep 9 | 2 days | Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFF | SSale | −51.2K | $10.92 | −$559.4K | −40.9%74.0K after | 10b5-1 |
| Nov 12, 2025 (view filing) | Nov 11 | 1 day | Feehery William FCHIEF EXECUTIVE OFFICER | PPurchase | +24.1K | $8.30 | +$200.0K | +1.0%2.36M after |